Cannabis Chewing Gum Enters Irritable Bowel Syndrome Trial

CanChew Plus CBD gum may eventually treat irritable bowel disease, Crohn’s disease, and ulcerative colitis.

Clinical trials have officially begun for the first-ever study of a cannabis chewing gum in patients with irritable bowel syndrome (IBS), according to an AXIM Biotechnologies press release.

The study will examine the efficacy of CanChew Plus CBD gum in alleviating IBS symptoms.

CanChew Plus is a non-habit forming, hemp-derived CBD functional chewing gum that is available in all 50 states. The gum will be tested along with matching placebo gums.

The study will include 40 patients aged 18 to 85 years who were diagnosed with IBS, according to the ROME III criteria, the release noted.

The CBD gum will contain 50 mg of CBD and patients will be allowed to take up to 6 chewing gums per day to help control bloating, stomach cramps, pain, and other IBS symptoms. The perceived outcome is pain reduction. According to the release, the study will also examine general relief and changes in stool frequency.

A positive outcome from the clinical trial will allow AXIM to proceed with further studies on the CanChewRX products to treat inflammatory bowel disease, Crohn’s disease, and ulcerative colitis, the press release states.

IBS is the most common functional gastrointestinal disorder, and affects up to 23% of individuals worldwide. Currently, there is no sustainable cure.